- Home
- IBRX vs UTF Comparison
IBRX vs UTF Comparison
Compare IBRX & UTF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- UTF
- Stock Information
- Founded
- IBRX 2014
- UTF 2004
- Country
- IBRX United States
- UTF United States
- Employees
- IBRX N/A
- UTF N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- UTF Finance Companies
- Sector
- IBRX Health Care
- UTF Finance
- Exchange
- IBRX Nasdaq
- UTF Nasdaq
- Market Cap
- IBRX 2.3B
- UTF 2.6B
- IPO Year
- IBRX N/A
- UTF N/A
- Fundamental
- Price
- IBRX $2.31
- UTF $26.61
- Analyst Decision
- IBRX Strong Buy
- UTF
- Analyst Count
- IBRX 5
- UTF 0
- Target Price
- IBRX $10.20
- UTF N/A
- AVG Volume (30 Days)
- IBRX 9.0M
- UTF 171.7K
- Earning Date
- IBRX 08-05-2025
- UTF 01-01-0001
- Dividend Yield
- IBRX N/A
- UTF 7.19%
- EPS Growth
- IBRX N/A
- UTF N/A
- EPS
- IBRX N/A
- UTF 2.84
- Revenue
- IBRX $56,600,000.00
- UTF $138,636,669.00
- Revenue This Year
- IBRX $629.94
- UTF N/A
- Revenue Next Year
- IBRX $109.91
- UTF N/A
- P/E Ratio
- IBRX N/A
- UTF $9.16
- Revenue Growth
- IBRX 4227.22
- UTF 19.80
- 52 Week Low
- IBRX $1.83
- UTF $22.05
- 52 Week High
- IBRX $7.48
- UTF $26.53
- Technical
- Relative Strength Index (RSI)
- IBRX 45.80
- UTF 44.88
- Support Level
- IBRX $2.17
- UTF $26.40
- Resistance Level
- IBRX $2.43
- UTF $27.11
- Average True Range (ATR)
- IBRX 0.15
- UTF 0.22
- MACD
- IBRX 0.00
- UTF -0.05
- Stochastic Oscillator
- IBRX 27.92
- UTF 28.08
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About UTF Cohen & Steers Infrastructure Fund Inc
Cohen & Steers Infrastructure Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is total return with an emphasis on income. It invests majority of its managed assets in securities issued by infrastructure companies, which consists of utilities, pipelines, toll roads, airports, railroads, ports, telecommunications companies, and other infrastructure companies, under normal market conditions.